Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. In this Perspective, we
今天阅读了《Trends in peptide drug discovery》这篇综述 网页链接 目前多肽药物开发龙头企业 Bicycle 和 PeptiDream 是值得关注的企业,其中 PeptiDream 仅在 2021 就与外界达成了 50 多亿美元的交易。 文章总结了理想多肽药物的主要特征及理想靶点的特点:
It also emphasizes examples where time〆xtension strategies and alternative delivery routes have helped establish and strengthen the position of peptide drugs in competitive markets. Finally, the chapter explores two novel trends in peptide drug discovery, macrocyclic and cell﹑enetrating peptides, both...
in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug–drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on ...
Proteins and peptides have a great potential as therapeutic agents; they have higher efficiency and lower toxicity, compared to chemical drugs. However, th
The 224 (56%) non-olfactory GPCRs that are yet to be explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders. Further trends in GPCR drug discovery can be analysed in an interactive resource in the GPCRdb database. ...
The 224 (56%) non-olfactory GPCRs that are yet to be explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders. Further trends in GPCR drug discovery can be analysed in an interactive resource in the GPCRdb database. ...
Though recombinant proteins and peptides account for increasing sales rates, the superiority of low-molecular mass compounds in human diseases therapy remains undisputed mainly due to more favorable compliance and bioavailability properties. In the past, new therapeutic approaches often derived from natural...
Additionally, PeptiDream and Novartis signed a $2.89 billion agreement in April 2024, expanding their previous partnership to include peptide-drug conjugates. These agreements highlight a strategic move toward leveraging peptide discovery platforms and bispecific antibody technologies to tackle complex cancer...
In June 2019,Novartis AG and PeptiDream Inc. signed a new Peptide Drug Conjugate "PDC" collaboration agreement to initiate macrocyclic peptide discovery, which will be used to address therapeutic and diagnostic applications. Get Specific Chapter/Information From The Report:https:/...